HitGen Inc. (SHA:688222)

China flag China · Delayed Price · Currency is CNY
27.12
+0.59 (2.22%)
At close: Mar 6, 2026
Market Cap10.83B +85.0%
Revenue (ttm)525.57M +23.1%
Net Income114.02M +122.0%
EPS0.28 +115.4%
Shares Out399.44M
PE Ratio96.86
Forward PE98.62
Dividend0.06 (0.23%)
Ex-Dividend Daten/a
Volume10,411,490
Average Volume10,046,082
Open26.35
Previous Close26.53
Day's Range26.23 - 27.66
52-Week Range11.85 - 42.98
Beta0.48
RSI38.27
Earnings DateApr 29, 2026

About HitGen

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline also includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 492
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688222
Full Company Profile

Financial Performance

In 2025, HitGen's revenue was 525.57 million, an increase of 23.09% compared to the previous year's 426.99 million. Earnings were 114.02 million, an increase of 122.01%.

Financial Statements